search
Tagrisso
Trends
- 1Hansoh lung cancer drug loses EU approval after AstraZeneca challenge●Hansoh’s Tagrisso rival loses EU approval after AstraZeneca legal challenge
Hansoh Pharmaceutical's copy of AstraZeneca's lung cancer drug Tagrisso has lost its European Union approval following a successful legal challenge by AstraZeneca. The decision removes the Chinese drugmaker's competing osimertinib-like therapy from the EU market and represents a significant win for AstraZeneca in defending its blockbuster oncology franchise.